Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05136092 · ClinicalTrials.gov registry record · NA

A Pilot Study to Determine Fructose Uptake by Primary Human Colorectal Tumors

A NA study of Colorectal Tumors, sponsored by Weill Medical College of Cornell University.

Completed
Registry status
NA
Development phase
12
Enrollment target
1
Study location

NCT05136092 is a NA study of Colorectal Tumors that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05136092, a NA study of Colorectal Tumors, has completed, sponsored by Weill Medical College of Cornell University.

COMPLETED
Registry status
NA
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

This proposed study is designed to investigate the specific uptake of fructose by human colorectal tumors. In this study, subjects with colorectal cancer undergoing surgery will receive an oral sugar solution containing fructose or xylose prior to surgery. The tumor will then be resected, and a portion of the tissue will be used to measure the abundance of fructose and xylose. The study hypothesis is that the tumors will take up fructose sugar but not xylose sugar. A comparison of the sugar uptake between the tumor and normal tissues from the adjacent intestinal epithelium and smooth muscle and the liver will be conducted. This proposal will confirm that human colorectal cancer tumors can directly absorb dietary sugars, which has never been demonstrated.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Cohort 1: HFCS (fructose) fed
  • DIETARY_SUPPLEMENT Cohort 2: D-Xylose (xylose-fed)

Study Locations (1)

New York

  • Weill Cornell Medicine - New York

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2022-02-16
Est. Completion 2024-09-27
Phase NA

What the Registry Record Tells You About NCT05136092

The ClinicalTrials.gov registry entry for NCT05136092 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Colorectal Tumors appearing as the primary indexed condition, and to 2 interventions - of which Cohort 1: HFCS (fructose) fed is the first listed.

NCT05136092 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT05136092 about?

NCT05136092 is a clinical study titled "A Pilot Study to Determine Fructose Uptake by Primary Human Colorectal Tumors". This proposed study is designed to investigate the specific uptake of fructose by human colorectal tumors. In this study, subjects with colorectal cancer undergoing surgery will receive an oral sugar solution containing fructose or xylose prior to surgery. The tumor will then be resected, and a port...

What is the current status of trial NCT05136092?

This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2022-02-16. Estimated completion is 2024-09-27.

What conditions does trial NCT05136092 study?

This clinical trial studies the following conditions: Colorectal Tumors.

What interventions are being tested in trial NCT05136092?

The interventions under investigation include: Cohort 1: HFCS (fructose) fed (DIETARY_SUPPLEMENT), Cohort 2: D-Xylose (xylose-fed) (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT05136092?

This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05136092 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.